Abstract:Xiaoqin Wei, 1, &ast Fang Wang, 2, &ast Ying Liu, 3 Zeyong Li, 4 Zhong Xue, 2 Mingyue Tang, 5 Xiaowen Chen 1 1 School of Medical Imaging, North Sichuan Medical College, Nanchong City, Sichuan Province, People's Republic of China; 2 Department of Research and Development, Shanghai United Imaging Intelligence Co., Ltd, Shanghai, People's Republic of China; 3 Department of Radiology, The First Affiliated Hospital of Chengdu Medical College, Chengdu City, Sichuan Province, People's Republic of China; 4 Department of Radiology, Bishan Hospital of Chongqing Medical University, ChongQing, People's Republic of China; 5 Department of Physics, School of Basic Medicine, North Sichuan Medical College, Nanchong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaowen Chen, School of Medical Imaging, North Sichuan Medical College, 234 Fujiang Road, Nanchong City, Sichuan Province, People's Republic of China, 637001, Email Purpose: To predict the efficacy of patients treated with hepatectomy and transarterial chemoembolization (TACE) based on machine learning models using clinical and radiomics features. Patients and Methods: Patients with HCC whose first treatment was hepatectomy or TACE from June 2016 to July 2021 were collected in the retrospective cohort study. To ensure a causal effect of treatment effect and treatment modality, perfectly matched patients were obtained according to the principle of propensity score matching and used as an independent test cohort. Inverse probability of treatment weighting was used to control bias for unmatched patients, and the weighted results were used as the training cohort. Clinical characteristics were selected by univariate and multivariate analysis of cox proportional hazards regression, and radiomics features were selected using correlation analysis and random survival forest. The machine learning models (Death hepatectomy and Death TACE ) were constructed to predict the probability of patient death after treatment (hepatectomy and TACE) by combining clinical and radiomics features, and an optimal treatment regimen was recommended. In addition, a prognostic model was constructed to predict the survival time of all patients. Results: A total of 418 patients with HCC who received either hepatectomy (n=267, mean age, 58 years ± 11 [standard deviation]; 228 men) or TACE (n=151, mean age, 59 years ± 13 [standard deviation]; 127 men) were recruited. After constructing the machine learning models Death hepatectomy and Death TACE , patients were divided into the hepatectomy-preferred and TACE-preferred groups. In the hepatectomy-preferred group, hepatectomy had a significantly prolonged survival time than TACE (training cohort: P < 0.001; testing cohort: P < 0.001), and vise versa for the TACE-preferred group. In addition, the prognostic model yielded high predictive capability for overall survival. Conclusion: The machine learning models could predict the outcomes difference between hepatectomy and TACE, and prognostic models could predict the overall survival for HCC patients. Keywords: radiomics, hepatocellular carcinoma, prognosis, hepatectomy Different treatment guidelines were proposed to provide appropriate treatment options for hepatocellular carcinoma (HCC) patients, such as China Liver Cancer (CNLC) staging 1 and Barcelona Clinic Liver Cancer (BCLC) staging. 2 However, they might be inadequate for clinical decision-making. First, there is disagreement among treatment guidelines over the recommended treatment regimens. In CNLC, hepatectomy is recommended for patients with Ia, Ib, and IIa stages, and transarterial chemoembolization (TACE) is recommended for patients with IIb, IIIa, and some IIIb stages. 1 In BCLC, patients with Ia and Ib stages are defined as 0 or A stage, IIa and IIb are defined as B stage, and IIIa and IIIb are defined as C stage. 2 Hepatectomy, TACE, and systemic treatments are recommended for different stages respectively. 2 Second, there exists heterogeneity among patients at the same stage, and survival times for patients even with the same treatment regimen are different. 3,4 Finally, in clinical practice, 50% of patients have deviated from their original recommendations based on the treatment guidelines. 4,5 Therefore, the treatment regimens for HCC patients are still unclear. Several studies 6–10 have found that TACE and hepatectomy have similar survival rates for patients with early-stage HCC. The question of which treat -Abstract Truncated-

Development of Ensemble Learning Models for Prognosis of Hepatocellular Carcinoma Patients Underwent Postoperative Adjuvant Transarterial Chemoembolization

Enhancing prognostic prediction in hepatocellular carcinoma post-TACE: a machine learning approach integrating radiomics and clinical features

Development and Validation of a Prediction Model for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients Receiving Postoperative Adjuvant Transarterial Chemoembolization

Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization

Development and validation of an ensemble machine-learning model for predicting early mortality among patients with bone metastases of hepatocellular carcinoma

Development and Validation of a Risk Prediction Algorithm for Evaluating the Efficacy of Postoperative Adjuvant TACE Therapy for Hepatocellular Carcinoma

Development and Validation of a Deep Learning Model for Survival Prognosis of Transcatheter Arterial Chemoembolization in Patients with Intermediate-Stage Hepatocellular Carcinoma

Serum alanine aminotransferase to hemoglobin ratio and radiological features predict the prognosis of postoperative adjuvant TACE in patients with hepatocellular carcinoma

Predicting postoperative liver cancer death outcomes with machine learning

A Machine Learning-Based Model to Predict Survival after Transarterial Chemoembolization for BCLC Stage B Hepatocellular Carcinoma

Development of a machine learning-based model for predicting risk of early postoperative recurrence of hepatocellular carcinoma

A New Prediction Model for Prognosis of Patients with Intermediate HCC after Conventional Transarterial Chemoembolization.

Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection

Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma

A Deep Learning Model Combining Multimodal Factors to Predict the Overall Survival of Transarterial Chemoembolization

A New Prediction Model for Prognosis of Patients with Intermediate-Stage HCC after Conventional Transarterial Chemoembolization: an Internally Validated Study.

A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization

A Machine Learning Model Based on Counterfactual Theory for Treatment Decision of Hepatocellular Carcinoma Patients

Prediction of Postoperative Survival Time of Hepatocellular Carcinoma Patients Based on Machine Learning

Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization

Development and Validation of Deep Learning Model for Intermediate-Stage Hepatocellular Carcinoma Survival with Transarterial Chemoembolization (Mc-Hccai 002): a Retrospective, Multicenter, Cohort Study.